FDA rejects serelaxin for acute heart failure The Oncology Report The Food and Drug Administration has decided that more evidence of serelaxin's efficacy as a treatment for acute heart failure is needed before the drug can be approved in the United States, Novartis Pharmaceuticals announced May 16. Serelaxin is a ... |
